In-vitro activity of polymyxin B, rifampicin, tigecycline alone and in combination against Carbapenem-resistant Acinetobacter baumannii in Singapore

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Lim, Tze Peng ^a,c   Tan, Thean Yen ^b   Lee, Winnie ^a   Sasikala, S ^b   Tan, Thuan Tong ^a   Hsu, Li Yang ^c   Kwa, Andrea L ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b CHANGI GENERAL HOSPITAL   (Singapore)

^c Dept Medicine Endocrinol Diabet   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

POLYMYXIN B; RIFAMPICIN; TIGECYCLINE; ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE; DRUG DERIVATIVE; MINOCYCLINE;

ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MULTIDRUG RESISTANCE; NONHUMAN; SINGAPORE; CLASSIFICATION; DRUG EFFECT;

ACINETOBACTER BAUMANNII;

ACINETOBACTER BAUMANNII; ANTI-BACTERIAL AGENTS; CARBAPENEMS; DRUG RESISTANCE, MICROBIAL; MINOCYCLINE; POLYMYXIN B; RIFAMPIN; SINGAPORE;

EID: 79955418678     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0018485     Document Type: Article

References (32)

1. Peleg AY, Seifert H, Paterson DL, (2008) Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 21: 538-582.
2. Bergogne-Berezin E, Towner KJ, (1996) Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev 9: 148-165.
3. Kuo LC, Lai CC, Liao CH, Hsu CK, Chang YL, et al. (2007) Multidrug-resistant Acinetobacter baumannii bacteraemia: clinical features, antimicrobial therapy and outcome. Clin Microbiol Infect 13: 196-198.
4. Kwa AL, Low JG, Lee E, Kurup A, Chee HL, et al. (2007) The impact of multidrug resistance on the outcomes of critically ill patients with Gram-negative bacterial pneumonia. Diagn Microbiol Infect Dis 58: 99-104.
5. Lolans K, Rice TW, Munoz-Price LS, Quinn JP, (2006) Multicity outbreak of carbapenem-resistant Acinetobacter baumannii isolates producing the carbapenemase OXA-40. Antimicrob Agents Chemother 50: 2941-2945.
6. Villegas MV, Kattan JN, Correa A, Lolans K, Guzman AM, et al. (2007) Dissemination of Acinetobacter baumannii clones with OXA-23 Carbapenemase in Colombian hospitals. Antimicrob Agents Chemother 51: 2001-2004.
7. Hawley JS, Murray CK, Jorgensen JH, (2008) Colistin heteroresistance in acinetobacter and its association with previous colistin therapy. Antimicrob Agents Chemother 52: 351-352.
8. Li J, Rayner CR, Nation RL, Owen RJ, Spelman D, et al. (2006) Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 50: 2946-2950.
9. Pachon-Ibanez ME, Jimenez-Mejias ME, Pichardo C, Llanos AC, Pachon J, (2004) Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem. Antimicrob Agents Chemother 48: 4479-4481.
10. Tan LW TT, Hsu LY, Koh TH, (2008) Characterization of resistance genes among Acinetobacter spp. isolates in Singaporean Hospitals. Barcelona Spain.
11. Chen TL, Siu LK, Wu RC, Shaio MF, Huang LY, et al. (2007) Comparison of one-tube multiplex PCR, automated ribotyping and intergenic spacer (ITS) sequencing for rapid identification of Acinetobacter baumannii. Clin Microbiol Infect 13: 801-806.
12. Clinical and Laboratory Standards Institute (2007) Performance standards for antimicrobial testing: Seventeenth Informational Supplement M100-S17. CLSI Wayne, Pennsylvania, USA.
13. Paterson DL, (2006) The epidemiological profile of infections with multidrug-resistant Pseudomonas aeruginosa and Acinetobacter species. Clin Infect Dis 43 (Suppl 2): S43-48.
14. Grundmann HJ, Towner KJ, Dijkshoorn L, Gerner-Smidt P, Maher M, et al. (1997) Multicenter study using standardized protocols and reagents for evaluation of reproducibility of PCR-based fingerprinting of Acinetobacter spp. J Clin Microbiol 35: 3071-3077.
15. Gumbo T, Louie A, Deziel MR, Liu W, Parsons LM, et al. (2007) Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob Agents Chemother 51: 3781-3788.
16. Zavascki AP, Goldani LZ, Cao G, Superti SV, Lutz L, et al. (2008) Pharmacokinetics of intravenous polymyxin B in critically ill patients. Clin Infect Dis 47: 1298-1304.
17. Rodvold KA, Gotfried MH, Cwik M, Korth-Bradley JM, Dukart G, et al. (2006) Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J Antimicrob Chemother 58: 1221-1229.
18. Clinical and Laboratory Standards Institute (1999) Methods for Determining Bactericidal Activity of Antimicrobial Agents; Approved Guidelines. CLSI Wayne, Pennsylvania, USA.
19. Paterson DL, Doi Y, (2007) A step closer to extreme drug resistance (XDR) in gram-negative bacilli. Clin Infect Dis 45: 1179-1181.
20. Chait R, Craney A, Kishony R, (2007) Antibiotic interactions that select against resistance. Nature 446: 668-671.
21. Sopirala MM, Mangino JE, Gebreyes WA, Biller B, Bannerman T, et al. (2010) Synergy testing by Etest, microdilution checkerboard, and time-kill methods for pan-drug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 54: 4678-4683.
22. Yoon J, Urban C, Terzian C, Mariano N, Rahal JJ, (2004) In vitro double and triple synergistic activities of Polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 48: 753-757.
23. Hogg GM, Barr JG, Webb CH, (1998) In-vitro activity of the combination of colistin and rifampicin against multidrug-resistant strains of Acinetobacter baumannii. J Antimicrob Chemother 41: 494-495.
24. Lim TP, Tan TY, Lee W, Sasikala S, Tan TT, et al. (2009) In vitro activity of various combinations of antimicrobials against carbapenem-resistant Acinetobacter species in Singapore. J Antibiot (Tokyo).
25. Montero A, Ariza J, Corbella X, Domenech A, Cabellos C, et al. (2004) Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model. J Antimicrob Chemother 54: 1085-1091.
26. Song JY, Kee SY, Hwang IS, Seo YB, Jeong HW, et al. (2007) In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother 60: 317-322.
27. Tascini C, Menichetti F, Bozza S, Del Favero A, Bistoni F, (1998) Evaluation of the activities of two-drug combinations of rifampicin, polymyxin B and ampicillin/sulbactam against Acinetobacter baumannii. J Antimicrob Chemother 42: 270-271.
28. Timurkaynak F, Can F, Azap OK, Demirbilek M, Arslan H, et al. (2006) In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units. Int J Antimicrob Agents 27: 224-228.
29. Pantopoulou A, Giamarellos-Bourboulis EJ, Raftogannis M, Tsaganos T, Dontas I, et al. (2007) Colistin offers prolonged survival in experimental infection by multidrug-resistant Acinetobacter baumannii: the significance of co-administration of rifampicin. Int J Antimicrob Agents 29: 51-55.
30. Kunin CM, Craig WA, Kornguth M, Monson R, (1973) Influence of binding on the pharmacologic activity of antibiotics. Ann N Y Acad Sci 226: 214-224.
31. (2010) (2010) Tygacil® (tigecycline) Prescribing Information, Wyeth Pharmaceuticals Inc.
32. Mendes RE, Fritsche TR, Sader HS, Jones RN, (2008) Increased antimicrobial susceptibility profiles among polymyxin-resistant Acinetobacter baumannii clinical isolates. Clin Infect Dis 46: 1324-1326.